Cognitive Function in a Randomized Trial of Evolocumab

To address concerns about cognitive decline with the use of PCSK9 inhibitors, automated neuropsychological testing was performed in patients who received evolocumab or placebo. Evolocumab was noninferior to placebo with respect to cognitive changes from baseline over 19 months.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine Jg. 377; H. 7; S. 633 - 643
Hauptverfasser: Giugliano, Robert P, Mach, François, Zavitz, Kenton, Kurtz, Christopher, Im, Kyungah, Kanevsky, Estella, Schneider, Jingjing, Wang, Huei, Keech, Anthony, Pedersen, Terje R, Sabatine, Marc S, Sever, Peter S, Robinson, Jennifer G, Honarpour, Narimon, Wasserman, Scott M, Ott, Brian R
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Massachusetts Medical Society 17.08.2017
Schlagworte:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents - adverse effects
Anticholesteremic Agents - therapeutic use
Atherosclerosis - drug therapy
Atherosclerosis - psychology
Cholesterol
Cholesterol, LDL - blood
Clinical trials
Cognition & reasoning
Cognition - drug effects
Cognitive ability
Double-Blind Method
Drug Therapy, Combination
Evidence-based medicine
Executive function
Female
Health risk assessment
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Kexin
Low density lipoprotein
Male
Memory - drug effects
Middle Aged
Monoclonal antibodies
PCSK9 Inhibitors
Proprotein convertases
Prospective Studies
Psychological Tests
Self-Assessment
Short term memory
Spatial memory
Statins
Subtilisin
ISSN:0028-4793, 1533-4406, 1533-4406
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To address concerns about cognitive decline with the use of PCSK9 inhibitors, automated neuropsychological testing was performed in patients who received evolocumab or placebo. Evolocumab was noninferior to placebo with respect to cognitive changes from baseline over 19 months.
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1701131